Eukaryotic mRNA processing — The mature mRNA from which source would be expected to carry a 3′ poly(A) tail?

Difficulty: Easy

Correct Answer: Human insulin mRNA transcribed in pancreatic beta cells

Explanation:


Introduction:
Polyadenylation is a hallmark of most eukaryotic mRNAs, enhancing stability, nuclear export, and translation. This question distinguishes eukaryotic mRNA processing from bacterial and phage transcripts.


Given Data / Assumptions:

  • Eukaryotic pre-mRNAs are typically 5′-capped, spliced, and 3′-polyadenylated.
  • Bacterial and bacteriophage mRNAs usually lack long 3′ poly(A) tails that function like eukaryotic poly(A); short polyadenylation in bacteria often marks decay.
  • Human insulin is a eukaryotic gene expressed in human cells.


Concept / Approach:
Identify the organismal origin of the mRNA. Eukaryotic mRNAs (e.g., human insulin mRNA) receive a poly(A) tail via poly(A) polymerase after cleavage at a consensus site; bacterial/phage transcripts generally do not have this eukaryotic-style modification.


Step-by-Step Solution:

1) Determine source: human vs bacterial/phage.2) Apply processing rule: eukaryotes → poly(A); bacteria/phage → typically no such tail for stability/translation.3) Conclude human insulin mRNA has a poly(A) tail.


Verification / Alternative check:
mRNA isolation protocols (oligo-dT selection) enrich eukaryotic polyadenylated transcripts such as insulin mRNA, confirming the presence of a poly(A) tail.


Why Other Options Are Wrong:

a,b,d) Prokaryotic/phage mRNAs lack canonical eukaryotic polyadenylation; any bacterial poly(A) often promotes decay.e) Many archaeal transcripts are not polyadenylated like eukaryotic mRNAs.


Common Pitfalls:
Assuming all RNAs have poly(A); conflating bacterial polyadenylation (RNA turnover) with eukaryotic stabilization.


Final Answer:
Human insulin mRNA.

Discussion & Comments

No comments yet. Be the first to comment!
Join Discussion